BioSpace News Archive

Compugen Ltd. announced today that on October 31, 2022 , it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

Omega Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company’s first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2022 financial results.

Coeptis Therapeutics Holdings, Inc. today announced the appointment of new directors to the Company’s board of directors (the “Board”) following the completion of the previously announced business combination between Coeptis Therapeutics, Inc. and the Company and initiation of trading of the Company’s common stock and public warrants under the trading symbols COEP and COEPW on the Nasdaq Global Market.

Versanis Bio today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego.

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2022 and updated certain financial expectations for full-year 2022. Alkermes today also announced its intent, as approved by its Board of Directors (the Board), to explore a separation of its commercial-stage neuroscience business and development-stage oncology business.

Bristol Myers Squibb announced the presentation of research demonstrating the strength of the company’s cardiovascular franchise at the American Heart Association’s annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates.

Sense and Biotecom Agree to Distribute Rapid, Instrument-Free Molecular Test, Veros COVID-19 in Chile.

CytoSorbents Corporation announced the presentation of the final key results from the U.S. multicenter CytoSorb Therapy in COVID-19 Registry at the 35th Annual Congress of the European Society of Intensive Care Medicine in Paris last week.